Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and Development

Autor: R Gomeni, M Beer, E Wang, Lutz Harnisch, C Franklin, R Kaye, Mike K. Smith, K Wolstencroft, E Watson, Stuart L. Moodie, Justin J. Wilkins, A Dunn, J Chard, ML Sardu, C Flandorfer, George Davey Smith, Sya Cheung, Pls Chan

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

Pharmacometric analyses are complex and multifactorial. It is essential to check, track, and document the vast amounts of data and metadata that are generated during these analyses (and the relationships between them) in order to comply with regulati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e9823a2cc7fc1a6a64e96d496fadef3
https://doi.org/10.1002/psp4.12171

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.

Autor: Gerhart J; Pfizer Inc, Research and Development, 500 Arcola Road, Collegeville, PA, 19424, USA. Jacqueline.Gerhart@pfizer.com., Cox DS; Pfizer Inc, Research and Development, 500 Arcola Road, Collegeville, PA, 19424, USA., Singh RSP; Pfizer Inc, Research and Development, Cambridge, MA, USA., Chan PLS; Pfizer R&D UK Limited, Sandwich, UK., Rao R; Pfizer Inc, Research and Development, Cambridge, MA, USA., Allen R; Pfizer Inc, Research and Development, Cambridge, MA, USA., Shi H; Pfizer Inc, Research and Development, Groton, CT, USA., Masters JC; Pfizer Inc, Research and Development, San Diego, CA, USA., Damle B; Pfizer Inc, Research and Development, New York, NY, USA.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Jan; Vol. 63 (1), pp. 27-42. Date of Electronic Publication: 2024 Jan 04.

Comparative assessment of viral dynamic models for SARS-CoV-2 for pharmacodynamic assessment in early treatment trials.

Autor: Agyeman AA; Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK., You T; Beyond Consulting Ltd., Cheshire, UK.; Medical Research Council, UK., Chan PLS; Pfizer, Sandwich, Kent, UK., Lonsdale DO; Department of Clinical Pharmacology, St George's University of London, London, UK.; Department of Intensive Care, St George's University Hospitals NHS Foundation Trust, London, UK., Hadjichrysanthou C; Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Mahungu T; Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, UK., Wey EQ; Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, UK.; Centre for Clinical Microbiology, Division of Infection and Immunity University College London, London, UK., Lowe DM; Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK.; Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, UK., Lipman MCI; Department of Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.; UCL Respiratory, University College London, Royal Free Campus, London, UK., Breuer J; Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.; Department of Microbiology, Great Ormond Street Hospital for Children, London, UK., Kloprogge F; Institute for Global Health, University College London, London, UK., Standing JF; Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.; Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Dec; Vol. 88 (12), pp. 5428-5433. Date of Electronic Publication: 2022 Sep 15.

Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.

Autor: Franzese RC; Certara Strategic Consulting, Raleigh, North Carolina, USA., McFadyen L; Pfizer, Sandwich, Kent, UK., Watson KJ; Certara Strategic Consulting, Sheffield, UK., Riccobene T; AbbVie, Madison, New Jersey, USA., Carrothers TJ; AbbVie, Madison, New Jersey, USA., Vourvahis M; Pfizer, New York, New York, USA., Chan PLS; Pfizer, Sandwich, Kent, UK., Raber S; Pfizer, La Jolla, California, USA., Bradley JS; Rady Children's Hospital/University of California San Diego School of Medicine, San Diego, California, USA., Lovern M; Certara Strategic Consulting, Raleigh, North Carolina, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Mar; Vol. 111 (3), pp. 635-645. Date of Electronic Publication: 2021 Nov 22.

The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.

Autor: Chan PLS; Pfizer, Sandwich, Kent, UK., McFadyen L; Pfizer, Sandwich, Kent, UK., Quaye A; Pfizer, Tadworth, Surrey, UK., Leister-Tebbe H; Pfizer, Collegeville, Pennsylvania, USA., Hendrick VM; Pfizer, Sandwich, Kent, UK., Hammond J; Pfizer, Collegeville, Pennsylvania, USA., Raber S; Pfizer, La Jolla, California, USA.

Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Jun; Vol. 10 (6), pp. 551-563. Date of Electronic Publication: 2021 May 01.